<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) is characterized by various clinical manifestations and by elevated levels of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Passive induction of APS by infusion of these antibodies has been demonstrated in animal models </plain></SENT>
<SENT sid="2" pm="."><plain>Intravenous immunoglobulin (IVIg) is one of the therapeutic options in APS </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, five commercially used preparations of IVIg were tested for the presence of elevated levels of <z:chebi fb="0" ids="28494">cardiolipin</z:chebi>, beta-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi>-I, phosphatidylserine, antinuclear, and <z:chebi fb="0" ids="4705">double-stranded DNA</z:chebi> autoantibodies, as well as for <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity </plain></SENT>
<SENT sid="4" pm="."><plain>The absence of abnormal elevated levels of any of these autoantibodies in five different IVIg preparations provides additional evidence for the safety of IVIg use in APS </plain></SENT>
</text></document>